Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?

by Amishi Y. Shah, Jose A. Karam, Zita D. Lim, Chaan S. Ng, Nizar M. Tannir
Published 2015-03-01

Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-An...

by Stepan M. Esagian, Ioannis A. Ziogas, Dimitrios Kosmidis, Mohammad D. Hossain, Nizar M. Tannir, Pavlos Msaouel
Published 2021-02-01

Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials

by Pavlos Msaouel, Nizar M. Tannir, Eric Jonasch, Hung Le, Andrew W Hahn, Omar Alhalabi, Erick Campbell
Published 2020-12-01

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions

by Jonathan Thouvenin, Nieves Martínez Chanzá, Omar Alhalabi, Hervé Lang, Nizar M. Tannir, Philippe Barthélémy, Gabriel G. Malouf
Published 2021-08-01

Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience

by Nidale Tarek, Rabih Said, Clark R. Andersen, Tina S. Suki, Jessica Foglesong, Cynthia E. Herzog, Nizar M. Tannir, Shreyaskumar Patel, Ravin Ratan, Joseph A. Ludwig, Najat C. Daw
Published 2020-10-01

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

by Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Published 2021-08-01

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

by Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Published 2021-09-01

Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma

by Ronan Flippot, Roger Mouawad, Jean-Philippe Spano, Morgan Rouprêt, Eva Compérat, Marc-Olivier Bitker, Jérôme Parra, Christophe Vaessen, Frederick Allanic, Quentin Manach, Nizar M. Tannir, David Khayat, Xiaoping Su, Gabriel G. Malouf
Published 2017-08-01

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma

by Andrew J. Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Pavlos Msaouel
Published 2021-04-01

BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation

by Tianhong Pan, Song-Chang Lin, Kai-Jie Yu, Guoyu Yu, Jian H. Song, Valerae O. Lewis, Justin E. Bird, Bryan Moon, Patrick P. Lin, Nizar M. Tannir, Eric Jonasch, Christopher G Wood, Gary E. Gallick, Li-Yuan Yu-Lee, Sue-Hwa Lin, Robert L. Satcher
Published 2018-01-01

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma

by Xian-De Liu, Wen Kong, Christine B. Peterson, Daniel J. McGrail, Anh Hoang, Xuesong Zhang, Truong Lam, Patrick G. Pilie, Haifeng Zhu, Kathryn E. Beckermann, Scott M. Haake, Sevinj Isgandrova, Margarita Martinez-Moczygemba, Nidhi Sahni, Nizar M. Tannir, Shiaw-Yih Lin, W. Kimryn Rathmell, Eric Jonasch
Published 2020-05-01

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders

by A. Boilève, M. I. Carlo, P. Barthélémy, S. Oudard, D. Borchiellini, M. H. Voss, S. George, C. Chevreau, J. Landman-Parker, M-D Tabone, D. D. Chism, A. Amin, M. A. Bilen, D. Bosse, A. Coulomb-L’hermine, Xiaoping Su, T. K. Choueiri, Nizar M. Tannir, Gabriel G. Malouf
Published 2018-12-01

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

by Howard Gurney, Thomas Powles, Laurence Albiges, Camillo Porta, Toni K Choueiri, Marc-Oliver Grimm, Elizabeth R Plimack, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Philippe Barthélémy, Christian K Kollmannsberger, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir, Mauricio Burotto, Daniel Castellano
Published 2020-12-01

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random...

by Howard Gurney, Thomas Powles, Asim Amin, Bohuslav Melichar, Camillo Porta, David F McDermott, Toni K Choueiri, Marc-Oliver Grimm, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Hans J Hammers, Saby George, Robert J Motzer, Alain Ravaud, Osvaldo Arén Frontera, Frede Donskov, Philippe Barthélémy, Victoria Neiman, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Raya Leibowitz-Amit, Poul F Geertsen, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir
Published 2020-07-01